Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Myofibroblasts produce the fibrous scar in hepatic fibrosis. In the carbon tetrachloride (CCl(4)) model of liver fibrosis, quiescent hepatic stellate cells (HSC) are activated to become myofibroblasts. When the underlying etiological agent is removed, clinical and experimental fibrosis undergoes a remarkable regression with complete disappearance of these myofibroblasts. Although some myofibroblasts apoptose, it is unknown whether other myofibroblasts may revert to an inactive phenotype during regression of fibrosis. We elucidated the fate of HSCs/myofibroblasts during recovery from CCl(4)- and alcohol-induced liver fibrosis using Cre-LoxP-based genetic labeling of myofibroblasts. Here we demonstrate that half of the myofibroblasts escape apoptosis during regression of liver fibrosis, down-regulate fibrogenic genes, and acquire a phenotype similar to, but distinct from, quiescent HSCs in their ability to more rapidly reactivate into myofibroblasts in response to fibrogenic stimuli and strongly contribute to liver fibrosis. Inactivation of HSCs was associated with up-regulation of the anti-apoptotic genes Hspa1a/b, which participate in the survival of HSCs in culture and in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, restored RSPO3 expression during HSC deactivation52,53 or by therapeutic interventions might help to regain hepatocyte functions.”
From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [52]
In the citing paper
“Animal models reinforce the capacity of the injured liver to regress fibrosis and provide important platform for dissecting underlying mechanisms, although it should be noted that fibrosis in mice regresses incredibly rapidly, which may be in part attributed to the short duration of models (weeks to months in mice vs. years to decades in humans) and initiation of fibrosis at relatively young age (”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [262]
In the citing paper
“Fibroblast activation also involves increased activity of key glycolytic enzymes, such as hexokinase 2 and lactate dehydrogenase (LDH)47, which in turn increase cell proliferation47 and collagen synthesis48.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [47]
In the citing paper
“During enhanced glycolysis, increased amounts of pyruvate are converted to acetyl-CoA in the mitochondrial matrix47 before entering the citric acid cycle. This yields intermediate metabolites, such as succinate, which promote fibrosis49.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [47]
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Self-citationSenescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Self-citationBataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Iredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075 · cited 8×
“Myofibroblasts are aSMA collagen type I cells that are absent from the normal uninjured liver, rapidly emerge infibrotic liver to produce thefibrous scar, and completely disappear with regression of liver fibrosis (1, 2).”
BackgroundInfluentialThe role of matrix stiffness in regulating cell behavior†
Wells, R. G. (2008) · Hepatology · doi:10.1002/hep.22193 · Cited by 1,059
Hepatic lipocytes: the principal collagen-producing cells of normal rat liver.
Friedman, S. L., Roll, F. J., Boyles, J., & Bissell, D. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8681 · Cited by 859
Lee, K. S., Buck, M., Houglum, K., & Chojkier, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118304 · Cited by 539
Ito Cells Are Liver-Resident Antigen-Presenting Cells for Activating T Cell Responses
Winau, F., Hegasy, G., Weiskirchen, R., Weber, S., Cassan, C., Sieling, P. A., Modlin, R. L., Liblau, R. S., Gressner, A. M., & Kaufmann, S. H. E. (2007) · Immunity · doi:10.1016/j.immuni.2006.11.011 · Cited by 410
Lee, C. G., Cho, S. J., Kang, M. J., Chapoval, S. P., Lee, P. J., Noble, P. W., Yehualaeshet, T., Lu, B., Flavell, R. A., Milbrandt, J., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040104 · Cited by 369
Cited by
Items 101–200 of 889
Ohtani, N., & Kawada, N. (2019) · Hepatology Communications · doi:10.1002/hep4.1331 · Cited by 187
“Mogler et al.(33) demonstrated that activated HSCs highly expressed the orphan receptor endosialin (CD248), which in turn attenuated the growth of hepatocellular carcinoma (HCC) and down-regulated cell proliferation-associated molecules, such as insulin-like growth factor 2, retroviral binding protein 4, Dickkopf-1, a…”
BackgroundInfluentialHuang, B., Cheng, X., Wang, H., Huang, W., la Ga hu, Z., Wang, D., Zhang, K., Zhang, H., Xue, Z., Da, Y., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0792-1 · Cited by 183
“For example, fibrous scar-produced myofibroblasts can revert into inactive phenotypes [25].”
Herum, K., Lunde, I., McCulloch, A., & Christensen, G. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6050053 · Cited by 179
Hepatic stellate cell senescence in liver fibrosis: Characteristics, mechanisms and perspectives
Zhang, M., Serna-Salas, S., Damba, T., Borghesan, M., Demaria, M., & Moshage, H. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111572 · Cited by 179
Myojin, Y., Hikita, H., Sugiyama, M., Sasaki, Y., Fukumoto, K., Sakane, S., Makino, Y., Takemura, N., Yamada, R., Shigekawa, M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.015 · Cited by 178
The complex mural cell: Pericyte function in health and disease
Dijk, C. V., Nieuweboer, F. E., Pei, J. Y., Xu, Y. J., Bürgisser, P. E., van Mulligen, E., el Azzouzi, H., Duncker, D. J., Verhaar, M. C., & Cheng, C. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.258 · Cited by 178
Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside
Rockey, D. C., & Friedman, S. L. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.065 · Cited by 156
Reversal of liver cirrhosis: current evidence and expectations
Jung, Y. K., & Yim, H. J. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.268 · Cited by 148
3D in vitro models of liver fibrosis
van Grunsven, L. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.004 · Cited by 177
Cellular Mechanisms of Tissue Fibrosis. 3. Novel mechanisms of kidney fibrosis
Campanholle, G., Ligresti, G., Gharib, S. A., & Duffield, J. S. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00414.2012 · Cited by 174
Reversal of liver fibrosis: From fiction to reality
Zoubek, M. E., Trautwein, C., & Strnad, P. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.04.005 · Cited by 174
Ito, S., & Nagata, K. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.tm118.002812 · Cited by 173
Carloni, V., Luong, T. V., & Rombouts, K. (2014) · Liver International · doi:10.1111/liv.12465 · Cited by 173
Friend or foe? The elusive role of hepatic stellate cells in liver cancer
Cogliati, B., Yashaswini, C. N., Wang, S., Sia, D., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00821-z · Cited by 148
The inflammatory speech of fibroblasts
Schuster, R., Rockel, J. S., Kapoor, M., & Hinz, B. (2021) · Immunological Reviews · doi:10.1111/imr.12971 · Cited by 172
Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development
(2015) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2014.00035 · Cited by 171
Alcoholic liver disease: Utility of animal models
Lamas-Paz, A., Hao, F., Nelson, L. J., Vázquez, M. T., Canals, S., Moral, M. G. D., Martínez-Naves, E., Nevzorova, Y. A., & Cubero, F. J. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i45.5063 · Cited by 171
Barkauskas, C. E., & Noble, P. W. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00321.2013 · Cited by 167
Characterization of animal models for primary sclerosing cholangitis (PSC)
Fickert, P., Pollheimer, M. J., Beuers, U., Lackner, C., Hirschfield, G., Housset, C., Keitel, V., Schramm, C., Marschall, H.-U., Karlsen, T. H., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.006 · Cited by 167
Liver Fibrosis: From Pathogenesis to Novel Therapies
Weiskirchen, R., & Tacke, F. (2016) · Digestive Diseases · doi:10.1159/000444556 · Cited by 156
Kollmannsberger, P., Bidan, C. M., Dunlop, J. W. C., Fratzl, P., & Vogel, V. (2018) · Science Advances · doi:10.1126/sciadv.aao4881 · Cited by 149
Kordes, C., & Häussinger, D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66027 · Cited by 148
Lai, K. K. Y., Kweon, S.-M., Chi, F., Hwang, E., Kabe, Y., Higashiyama, R., Qin, L., Yan, R., Wu, R. P., Lai, K., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.021 · Cited by 165
Self-citationThe perivascular origin of pathological fibroblasts
Di Carlo, S. E., & Peduto, L. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93558 · Cited by 164
“The use of collagen-driven Cre or Wt1-Cre allowed the identification of the mesenchymal compartment as the major source for myofibroblasts after injury (125).”
BackgroundKidney Pericytes: Roles in Regeneration and Fibrosis
Kramann, R., & Humphreys, B. D. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.06.004 · Cited by 156
Lua, I., Li, Y., Zagory, J. A., Wang, K. S., French, S. W., Sévigny, J., & Asahina, K. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.010 · Cited by 153
Bárcena, C., Stefanovic, M., Tutusaus, A., Joannas, L., Menéndez, A., García-Ruiz, C., Sancho-Bru, P., Marí, M., Caballeria, J., Rothlin, C. V., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.013 · Cited by 151
S100A4 promotes liver fibrosis via activation of hepatic stellate cells
Chen, L., Li, J., Zhang, J., Dai, C., Liu, X., Wang, J., Gao, Z., Guo, H., Wang, R., Lu, S., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.035 · Cited by 162
Origins and functions of liver myofibroblasts
Lemoinne, S., Cadoret, A., Mourabit, H. E., Thabut, D., & Housset, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.02.019 · Cited by 163
Chen, Y., Chang, Y.-T., Pan, S., Chou, Y., Chang, F., Yeh, P.-Y., Liu, Y.-H., Chiang, W., Chen, Y., Wu, K., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013101079 · Cited by 161
Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity
Payen, V. L., Lavergne, A., Alevra Sarika, N., Colonval, M., Karim, L., Deckers, M., Najimi, M., Coppieters, W., Charloteaux, B., Sokal, E. M., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100278 · Cited by 160
Apoptosis and angiogenesis: an evolving mechanism for fibrosis
Johnson, A., & DiPietro, L. A. (2013) · The FASEB Journal · doi:10.1096/fj.12-214189 · Cited by 160
Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies
Lurje, I., Gaisa, N. T., Weiskirchen, R., & Tacke, F. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101191 · Cited by 161
Mechanisms of Lung Fibrosis Resolution
Glasser, S. W., Hagood, J. S., Wong, S. S., Taype, C. A., Madala, S. K., & Hardie, W. D. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.01.018 · Cited by 160
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158
“…fibrosis in mice re-gresses incredibly rapidly, which may be in part attributed to the short duration of models (weeks to months in mice versus years to decades in humans) and initiation of fibrosis at relatively young age (with most studies completed before mice hit “ middle age ” ) ( 52 , 257 ).”
BackgroundNorona, L. M., Nguyen, D. G., Gerber, D. A., Presnell, S. C., & LeCluyse, E. L. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw169 · Cited by 144
Molecular networks underlying myofibroblast fate and fibrosis
Stempien-Otero, A., Kim, D.-H., & Davis, J. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.05.002 · Cited by 143
Fibrosis: cross-organ biology and pathways to development of innovative drugs
Rieder, F., Nagy, L. E., Maher, T. M., Distler, J. H. W., Kramann, R., Hinz, B., & Prunotto, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01158-9 · Cited by 154
Bhattacharya, M., & Ramachandran, P. (2023) · Nature Immunology · doi:10.1038/s41590-023-01551-9 · Cited by 148
Nishio, T., Hu, R., Koyama, Y., Liang, S., Rosenthal, S. B., Yamamoto, G., Karin, D., Baglieri, J., Ma, H.-Y., Xu, J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.012 · Cited by 135
Self-citationMultipotent stromal cells: One name, multiple identities
Soliman, H., Theret, M., Scott, W., Hill, L., Underhill, T. M., Hinz, B., & Rossi, F. M. V. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.09.001 · Cited by 147
Della‐Torre, E., Feeney, E. R., Deshpande, V., Mattoo, H., Mahajan, V. S., Kulikova, M., Wallace, Z. S., Carruthers, M. N., Chung, R. T., Pillai, S. S., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205799 · Cited by 146
Heterogeneity of HSCs in a Mouse Model of NASH
Rosenthal, S. B., Liu, X., Ganguly, S., Dhar, D., Pasillas, M. P., Ricciardelli, E., Li, R. Z., Troutman, T. D., Kisseleva, T., Glass, C. K., et al. (2021) · Hepatology · doi:10.1002/hep.31743 · Cited by 145
Self-citationLipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2
Ganguly, S., Rosenthal, S. B., Ishizuka, K., Troutman, T. D., Rohm, T. V., Khader, N., Aleman-Muench, G., Sano, Y., Archilei, S., Soroosh, P., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2405746121 · Cited by 145
“Therefore, to evaluate the effective reduction in collagen levels following the dietary switch, the SR score of each regression group was normalized to the corresponding MASH SR score (at 12 wk WD just before the switch) as previously reported for CCl 4 fibrosis resolution studies ( 33 ).”
Self-citationLee, Y. A., & Friedman, S. L. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.03.012 · Cited by 132
Yang, A.-T., Kim, Y.-O., Yan, X.-Z., Abe, H., Aslam, M., Park, K.-S., Zhao, X.-Y., Jia, J.-D., Klein, T., You, H., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.12.005 · Cited by 144
“Results Specific FAP Inhibition Attenuates Carbon Tetrachloride-induced Hepatic Injury We used a specific oral FAP inhibitor (FAPi)(22) in an optimized model of parenchymal liver fibrosis,(23) both during fibrosis progression and during recovery (partial regression) after toxin discontinuation.(6,7,23) The liver and s…”
MethodMechanisms for the Resolution of Organ Fibrosis
Horowitz, J. C., & Thannickal, V. J. (2018) · Physiology · doi:10.1152/physiol.00033.2018 · Cited by 144
Macrophage Phenotype in Liver Injury and Repair
Sun, Y. ‐., Li, X. ‐., Meng, X. ‐., Huang, C., Zhang, L., & Li, J. (2017) · Scandinavian Journal of Immunology · doi:10.1111/sji.12468 · Cited by 137
The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis
Karin, D., Koyama, Y., Brenner, D., & Kisseleva, T. (2016) · Differentiation · doi:10.1016/j.diff.2016.07.001 · Cited by 133
Self-citationYang, M. J., Qi, X., Li, N., Kaifi, J. T., Chen, S., Wheeler, A. A., Kimchi, E. T., Ericsson, A. C., Rector, R. S., Staveley-O’Carroll, K. F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35861-1 · Cited by 142
Renal erythropoietin-producing cells in health and disease
Souma, T., Suzuki, N., & Yamamoto, M. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00167 · Cited by 124
The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies
Xu, J., Liu, X., Koyama, Y., Wang, P., Lan, T., Kim, I.-G., Kim, I. H., Ma, H.-Y., & Kisseleva, T. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00167 · Cited by 126
Self-citationMicroRNA‐101 suppresses liver fibrosis by targeting the TGF β signalling pathway
Tu, X., Zhang, H., Zhang, J., Zhao, S., Zheng, X., Zhang, Z., Zhu, J., Chen, J., Dong, L., Zang, Y., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4373 · Cited by 125
Human hepatic stellate cell isolation and characterization
Shang, L., Hosseini, M., Liu, X., Kisseleva, T., & Brenner, D. A. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1404-4 · Cited by 137
Self-citationHepatic stellate cells control liver zonation, size and functions via R-spondin 3
Sugimoto, A., Saito, Y., Wang, G., Sun, Q., Yin, C., Lee, K. H., Geng, Y., Rajbhandari, P., Hernandez, C., Steffani, M., et al. (2025) · Nature · doi:10.1038/s41586-025-08677-w · Cited by 133
New Developments on the Treatment of Liver Fibrosis
Koyama, Y., Xu, J., Liu, X., & Brenner, D. A. (2016) · Digestive Diseases · doi:10.1159/000445269 · Cited by 117
Self-citationLiu, X., Mi, X., Wang, Z., Zhang, M., Hou, J., Jiang, S., Wang, Y., Chen, C., & Li, W. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2597-7 · Cited by 123
Hepatic Stellate Cell Regulation of Liver Regeneration and Repair
Kitto, L. J., & Henderson, N. C. (2021) · Hepatology Communications · doi:10.1002/hep4.1628 · Cited by 117
Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice
Lazaro, R., Wu, R., Lee, S., Zhu, N., Chen, C., French, S. W., Xu, J., Machida, K., & Tsukamoto, H. (2015) · Hepatology · doi:10.1002/hep.27383 · Cited by 120
Self-citationMatrix Biology of Idiopathic Pulmonary Fibrosis
Thannickal, V. J., Henke, C. A., Horowitz, J. C., Noble, P. W., Roman, J., Sime, P. J., Zhou, Y., Wells, R. G., White, E. S., & Tschumperlin, D. J. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.02.003 · Cited by 117
Substrate Rigidity Controls Activation and Durotaxis in Pancreatic Stellate Cells
Lachowski, D., Cortes, E., Pink, D., Chronopoulos, A., Karim, S. A., P. Morton, J., & del Río Hernández, A. E. (2017) · Scientific Reports · doi:10.1038/s41598-017-02689-x · Cited by 105
Cuvellier, M., Ezan, F., Oliveira, H., Rose, S., Fricain, J.-C., Langouët, S., Legagneux, V., & Baffet, G. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120611 · Cited by 126
D’Arcangelo, E., Wu, N. C., Cadavid, J. L., & McGuigan, A. P. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0705-1 · Cited by 126
Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy
Lin, Y., Yan, M., Bai, Z., Xie, Y., Ren, L., Wei, J., Zhu, D., Wang, H., Liu, Y., Luo, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01636-x · Cited by 125
“The good plasticity of HSCs lies in the fact that the activated phenotype can undergo morphologic and biochemical reversal to a quiescent state [8, 10].”
BackgroundMesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis
Koyama, Y., Wang, P., Liang, S., Iwaisako, K., Liu, X., Xu, J., Zhang, M., Sun, M., Cong, M., Karin, D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88845 · Cited by 111
Self-citationAlimperti, S., Mirabella, T., Bajaj, V., Polacheck, W., Pirone, D. M., Duffield, J., Eyckmans, J., Assoian, R. K., & Chen, C. S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618333114 · Cited by 122
Modulation of hepatic stellate cells and reversibility of hepatic fibrosis
Huang, Y., Deng, X., & Liang, J. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.02.038 · Cited by 122
Cardiac valve cells and their microenvironment—insights from in vitro studies
Wang, H., Leinwand, L. A., & Anseth, K. S. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.162 · Cited by 104
Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities
Pei, Q., Yi, Q., & Tang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119671 · Cited by 121
“Consequently, targeting the deactivation of aHSCs has become a novel and effective method for liver fibrosis resolution [76,97].”
BackgroundMethodInfluentialMorán‐Salvador, E., Titos, E., Rius, B., González‐Périz, A., García‐Alonso, V., López‐Vicario, C., Miquel, R., Barak, Y., Arroyo, V., & Clària, J. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.023 · Cited by 123
Functional Immune Anatomy of the Liver—As an Allograft
Demetris, A. J., Bellamy, C. O. C., Gandhi, C. R., Prost, S., Nakanuma, Y., & Stolz, D. B. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13749 · Cited by 115
Stellate Cells in Tissue Repair, Inflammation, and Cancer
Sherman, M. H. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062855 · Cited by 103
Zisser, A., Ipsen, D. H., & Tveden-Nyborg, P. (2021) · Biomedicines · doi:10.3390/biomedicines9040365 · Cited by 104
Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies
Di, X., Li, Y., Wei, J., Li, T., & Liao, B. (2024) · Advanced Science · doi:10.1002/advs.202410416 · Cited by 124
Wu, Y., Liu, X., Zhou, Q. Y., Huang, C., Meng, X., Xu, F., & Li, J. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.09.028 · Cited by 121
Povero, D., Pinatel, E. M., Leszczynska, A., Goyal, N. P., Nishio, T., Kim, J., Kneiber, D., de Araujo Horcel, L., Eguchi, A., Ordonez, P. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125652 · Cited by 114
Self-citationInhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis
Shih, D. Q., Zheng, L., Zhang, X., Zhang, H., Kanazawa, Y., Ichikawa, R., Wallace, K. L., Chen, J., Pothoulakis, C., Koon, H. W., et al. (2014) · Mucosal Immunology · doi:10.1038/mi.2014.37 · Cited by 117
HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases
Yoon, S., Kang, G., & Eom, G. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061329 · Cited by 117
Repurposing of drugs as STAT3 inhibitors for cancer therapy
Thilakasiri, P. S., Dmello, R. S., Nero, T. L., Parker, M. W., Ernst, M., & Chand, A. L. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.022 · Cited by 117
In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations
Lee, Y.-S., & Seki, E. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.05.010 · Cited by 94
Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts
Liu, X., Xu, J., Brenner, D. A., & Kisseleva, T. (2013) · Current Pathobiology Reports · doi:10.1007/s40139-013-0018-7 · Cited by 115
Self-citationSchwabe, R. F., & Brenner, D. A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01068-6 · Cited by 112
Self-citationHDAC inhibitors in experimental liver and kidney fibrosis
Beneden, K. V., Mannaerts, I., Pauwels, M., Branden, C. V. D., & van Grunsven, L. A. (2013) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-6-1 · Cited by 114
Panebianco, C., Oben, J. A., Vinciguerra, M., & Pazienza, V. (2016) · Clinical and Experimental Medicine · doi:10.1007/s10238-016-0438-x · Cited by 112
Barcena-Varela, M., Paish, H., Alvarez, L., Uriarte, I., Latasa, M. U., Santamaria, E., Recalde, M., Garate, M., Claveria, A., Colyn, L., et al. (2021) · Gut · doi:10.1136/gutjnl-2019-320205 · Cited by 93
Guvendiren, M., Perepelyuk, M., Wells, R. G., & Burdick, J. A. (2014) · Journal of the Mechanical Behavior of Biomedical Materials · doi:10.1016/j.jmbbm.2013.11.008 · Cited by 102
Gradually softening hydrogels for modeling hepatic stellate cell behavior during fibrosis regression
Caliari, S. R., Perepelyuk, M., Soulas, E. M., Lee, G. Y., Wells, R. G., & Burdick, J. A. (2016) · Integrative Biology · doi:10.1039/c6ib00027d · Cited by 97
The Role of Pericyte Detachment in Vascular Rarefaction
Schrimpf, C., Teebken, O. E., Wilhelmi, M., & Duffield, J. S. (2014) · Journal of Vascular Research · doi:10.1159/000365149 · Cited by 101
Kuo, C., Chiu, V. J.-Y., Hsieh, P., Chun-Yen, H., Huang, S.-T. J., Tzeng, I., Tsai, F., Chen, M., Liu, C.-T., & Chen, Y.-R. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.07.014 · Cited by 106
Fallowfield, J. A., Hayden, A. L., Snowdon, V. K., Aucott, R. L., Stutchfield, B. M., Mole, D. J., Pellicoro, A., Gordon-Walker, T. T., Henke, A., Schrader, J., et al. (2014) · Hepatology · doi:10.1002/hep.26627 · Cited by 95
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
Knorr, J., Kaufmann, B., Inzaugarat, M. E., Holtmann, T. M., Geisler, L., Hundertmark, J., Kohlhepp, M. S., Boosheri, L. M., Chilin‐Fuentes, D. R., Birmingham, A., et al. (2023) · Hepatology · doi:10.1002/hep.32776 · Cited by 92
Zhang, Z., Yuan, Y., Hu, L., Tang, J., Meng, Z., Dai, L., Gao, Y., Ma, S., Wang, X., Yuan, Y., et al. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.08.006 · Cited by 102
In vitro reversion of activated primary human hepatic stellate cells
El Taghdouini, A., Najimi, M., Sancho-Bru, P., Sokal, E., & van Grunsven, L. A. (2015) · Fibrogenesis & Tissue Repair · doi:10.1186/s13069-015-0031-z · Cited by 91
Kawasaki, K., Ushioda, R., Ito, S., Ikeda, K., Masago, Y., & Nagata, K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.592139 · Cited by 94
San‐Miguel, B., Crespo, I., Sánchez, D. I., González‐Fernández, B., Ortiz de Urbina, J. J., Tuñón, M. J., & González‐Gallego, J. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12247 · Cited by 96
RetractedKarsdal, M. A., Krarup, H., Sand, J. M. B., Christensen, P. B., Gerstoft, J., Leeming, D. J., Weis, N., Schaffalitzky de Muckadell, O. B., & Krag, A. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12820 · Cited by 95
Origins of fibrosis: pericytes take centre stage
Greenhalgh, S. N., Iredale, J. P., & Henderson, N. C. (2013) · F1000Prime Reports · doi:10.12703/p5-37 · Cited by 96
“in a study primarily designed to explore the fate of hepatic myofibroblasts during liver fibrosis regression, reported that HSCs are the major source of myofibroblasts in a murine model of liver fibrosis [37].”
BackgroundIdentifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma
Zhang, J., Gu, C., Song, Q., Zhu, M., Xu, Y., Xiao, M., & Zheng, W. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00488-y · Cited by 97
Transcriptional regulation of Hepatic Stellate Cell activation in NASH
Marcher, A.-B., Bendixen, S. M., Terkelsen, M. K., Hohmann, S. S., Hansen, M. H., Larsen, B. D., Mandrup, S., Dimke, H., Detlefsen, S., & Ravnskjaer, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-39112-6 · Cited by 95
Yashaswini, C. N., Qin, T., Bhattacharya, D., Amor, C., Lowe, S., Lujambio, A., Wang, S., & Friedman, S. L. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.03.014 · Cited by 83
Metadata
- Authors
- Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., Evans, S. M., Dillmann, W., Glass, C. K., & Brenner, D. A.
- Affiliations
- Department of Medicine,
- Universitätsklinikum Aachen (DE)
- Department of Cellular and Molecular Medicine,
- School of Pharmacy, University of California, San Diego, CA 92093;
- University of Southern California (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2012-05-07
- Volume
- 109
- Issue
- 24
- Pages
- 9448-9453
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3386114
- OpenAlex
- W2075290880
- Cited by
- 805
- References
- 27
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 61 · 2023: 59 · 2022: 53 · 2021: 62 · 2020: 64 · 2019: 52 · 2018: 53 · 2017: 61 · 2016: 64 · 2015: 73 · 2014: 63 · 2013: 42 · 2012: 13
- FWCI
- 38.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041804)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- myofibroblasts, hepatic stellate cells, liver fibrosis, fibrosis regression, apoptosis, anti-apoptotic genes, carbon tetrachloride, alcohol-induced liver injury, fibrogenic gene expression
- MeSH terms
- Animals, Liver Cirrhosis, Phenotype, Tamoxifen, Adoptive Transfer, Collagen Type I, Mice, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.